Allogene Therapeutics, Inc. (ALLO)

Allogene Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	-212.02	-257.59	-327.27	-340.41	-182.05	-316.38
Depreciation & Amortization	12.54	13.64	14.2	14.3	10.45	7.44
Asset Writedown & Restructuring Costs	2.38	15.72	13.25	-	-	0.15
Loss (Gain) From Sale of Investments	-3.09	-6.39	0.19	2.89	6.96	3.25
Loss (Gain) on Equity Investments	-	1.69	10.67	12.88	4.09	67.31
Stock-Based Compensation	42.39	51.74	65.95	83.6	80.82	65.26
Other Operating Activities	4.87	5.69	6.58	2.33	-73.13	3.96
Change in Accounts Payable	-1.8	-0.5	-7.5	4.87	-0.77	0.62
Change in Unearned Revenue	-	-	-	-0.02	-38.3	38.35
Change in Other Net Operating Assets	-3.61	-24.3	-13.81	-0.95	7.12	14.96
Operating Cash Flow	-158.35	-200.3	-237.73	-220.52	-184.81	-115.09
Capital Expenditures	-0.64	-0.69	-1.52	-5.19	-21.45	-65.96
Investment in Securities	117.52	76.38	164.81	111.35	185.1	-439.17
Investing Cash Flow	116.88	75.69	163.29	106.16	163.66	-505.12
Issuance of Common Stock	21.13	114.4	95.7	2.95	11.96	633.59
Other Financing Activities	6.91	2.28	-	-	-	-
Financing Cash Flow	28.04	116.68	95.7	2.95	11.96	633.59
Net Cash Flow	-13.42	-7.94	21.25	-111.41	-9.19	13.38
Free Cash Flow	-158.99	-200.99	-239.25	-225.71	-206.26	-181.05
Free Cash Flow Margin	-	-913609.09%	-251841.05%	-144685.90%	-180.79%	-
Free Cash Flow Per Share	-0.73	-1.03	-1.52	-1.58	-1.52	-1.50
Levered Free Cash Flow	-83.92	-99.13	-134.26	-111.74	-85.97	-97.89
Unlevered Free Cash Flow	-83.39	-99.02	-134.26	-111.74	-85.97	-97.89
Change in Working Capital	-5.41	-24.8	-21.31	3.9	-31.95	53.92

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q